Navigation Links
Tigecycline – New Generation Tetracycline With Broad Spectrum Antibacterial Activit

Richard Wenzel and his colleagues from United Kingdom have found a new antibiotic tigecycline which belongs to the family of new generation of Tetracycline known as Glycycline. //

Due to indiscriminate use of antibiotics there is an increased incidence of antibiotic resistance shown by many organisms. Staphylococcus aureus is a gram positive bacteria, which is a major cause of concern as it causes most of the nosocomial infections in hospital. Staphylococcus aureus as shown an increased resistance to many drugs including the different analogues of Tetracycline and Vancomycin.

Drug – Tetracycline: Tetracyclines were first discovered 50 years ago and were found to have broad spectrum antibacterial activity against both gram positive and gram negative bacteria. Following their initial widespread use, a high incidence of tetracycline resistance among many bacteria has led to tetracyclines being relegated to second- or third-line therapy. As increases resistance to tetracycline have developed there are lot of approaches to restore the potential of tetracyclines as broad-spectrum antibiotics, systematic searches for tetracycline analogues with activity against both tetracycline-susceptible and tetracycline-resistant organisms were performed in the early 1990s which has led to the identification of the glycylcyclines, including tigecycline.

Properties of Tigecycline: Tigecycline was discovered by introducing substituents at position 9 of minocycline resulted in compounds that not only had activity typical of earlier tetracyclines, but also displayed activity against bacteria containing resistant genes.

Tigecycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit. Tigecycline blocks entry of amino-acyl tRNA molecules into the A site of the ribosome, preventing incorporation of amino-acid residues into elongating peptide chains. Tetracycline drug resistance in bacteria occurred due to mechanisms of ribosomal protection and active drug efflux. But, the new generation tetracycline - Tigecycline is not affected by either of these mechanisms.

Clinical studies and FDA approval: Two clinical studies proving the active effect of Tigecycline as lead to FDA approval of Tigecycline for treatment of bacterial infections.

Study I: Tigecycline was tested on patients with complicated skin and skin-structure infections.

The study was performed in 800 adult patients. Tigecycline was given in a concentration of 100 mg intravenous initial dose followed by 50 mg every 12 hours which was compared with vancomycin 1 g intravenously every 12 hours/aztreonam 2 g intravenously every 12 hours for 5–14 days.

Study II: Tigecycline was tested in patients with complicated intra-abdominal infections

The study was performed in more than 1,000 adult patients. Tigecycline was given at a dosage of 100 mg intravenous initial dose followed by 50 mg every 12 hours which was compared with imipenem/cilastatin 500 mg intravenously every 6 hours for 5–14 days.

Tigecycline has great promise as a new therapeutic agent against important pathogens and is highly active against both nosocomial and Methicillin Resistant S. aureus strains (MRSA), vancomycin resistant E. faecium and penicillin resistant strains of S. pneumoniae. Though, Tigecycline's structure is similar to that of the tetracyclines but additional structural elements increase its potency and impede the mechanisms of bacterial resistance associated with the tetracyclines.

Source: Nature Reviews Drug Discovery
'"/>




Related medicine news :

1. Hearing Problems Of Middle Age Are Affecting The Younger Generation
2. Newer Generation Sleeping Pills Lack Superior Performance
3. New Generation Clinical Trials Could Save Time And Money, Improve Patient Care
4. Moles Among The Older Generation May Be Dangerous
5. Leptin, The Next Generation Antidepressant?
6. Generation Scotland To Examine Relation Between Lifestyle, Genetics and Health
7. Baby Gloom: ‘Baby Gap’ Generation Signals Babies’ Days Ot!
8. Researchers Aim To Develop Next Generation Of Surgical Robots
9. New Generation Teenagers Addiction to Prescription Drugs
10. New Generation - Medicinal Products
11. Take Third Generation Oral Contraceptives Off the Shelves-consumer Group Insists
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... ... 13, 2017 , ... Global Healthcare Management’s 4th Annual Kids Fun Run brought ... This free event, sponsored by Global Healthcare Management’s CEO, Jon Letko, is aimed at ... towards children of all ages; it is a non-competitive, non-timed event, which is all ...
(Date:10/13/2017)... ... , ... “America On The Brink”: the Christian history of the United States ... creation of published author, William Nowers. Captain Nowers and his wife, Millie, have ... thirty years in the Navy. Following his career as a naval aviator and ...
(Date:10/12/2017)... , ... October 12, 2017 , ... IsoComforter, Inc. ( ... announced today the introduction of an innovative new design of the shoulder pad. ... you get maximum comfort while controlling your pain while using cold therapy. By utilizing ...
(Date:10/12/2017)... ... 12, 2017 , ... HMP , a leader in healthcare events and ... Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie ... annual award competition recognizes editorial and design excellence across a range of sectors. This ...
(Date:10/12/2017)... ... 2017 , ... In the United States, single-family home owners ... New York, New Jersey, Massachusetts, Texas, Virginia, Connecticut, and California—the average is $7,000 ... property-tax rates, which contributes to the relatively lower cost of living in places ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... Halo Labs announces the European launch of their new low volume, ... 2017 in Cambridge, U.K on October 4th. ... samples with unprecedented speed and sensitivity while using far less sample ... ... system ...
(Date:9/27/2017)... , Sept. 27, 2017  Commended for their devotion to ... awards. Ranked as number one in the South Florida Business ... in Inc. 5000 yearly list, the national specialty pharmacy has ... Armando Bardisa will soon be honored by SFBJ as ... Set to receive his award in October, ...
(Date:9/23/2017)... Sept. 22, 2017 Janssen Biotech, Inc. (Janssen) ... letter from the U.S. Food and Drug Administration (FDA) ... sirukumab for the treatment of moderately to severely active ... clinical data are needed to further evaluate the safety ... active RA. ...
Breaking Medicine Technology: